Viscoelastic testing (VET) and fibrinogen concentrate use — the point-of-care rotational thromboelastometry (ROTEM) and thromboelastography (TEG) enabling real-time bedside fibrinogen function assessment driving goal-directed fibrinogen replacement — represents the most important clinical practice development enabling rational fibrinogen concentrate utilization, with the Fibrinogen Concentrate Market reflecting VET adoption as a critical commercial market enabler.

ROTEM-based fibrinogen algorithms — the cardiac surgery, trauma, and obstetric hemorrhage management algorithms using ROTEM FIBTEM clot amplitude to guide fibrinogen concentrate dosing — creating the standardized clinical pathway that drives fibrinogen concentrate procurement decisions. Hospitals implementing VET-guided algorithms documenting reduced total blood product use while maintaining hemostatic adequacy through targeted fibrinogen replacement.

TEG Functional Fibrinogen (TEG-FF) — the TEG platform's equivalent fibrinogen-specific assay enabling TEG-using centers to guide fibrinogen concentrate therapy — creating the alternative VET pathway to ROTEM-guided fibrinogen replacement. The Haemonetics TEG 6s system's cartridge-based testing enabling rapid bedside fibrinogen function assessment in operating rooms and intensive care units.

VET adoption driving fibrinogen concentrate market expansion — the correlation between hospital ROTEM/TEG adoption and fibrinogen concentrate procurement demonstrating the diagnostic-therapeutic ecosystem. Hospitals without VET capability using empirical cryoprecipitate while VET-enabled centers systematically using fibrinogen concentrate — creating the market expansion opportunity from further VET adoption.

Do you think universal VET adoption in all cardiac surgery, trauma, and obstetric centers will double or triple fibrinogen concentrate utilization through optimized goal-directed dosing?

FAQ

What is ROTEM and how does it guide fibrinogen concentrate use? ROTEM (Rotational Thromboelastometry): point-of-care coagulation analyzer measuring whole blood clot formation in real-time; relevant assays: EXTEM (overall clot strength), FIBTEM (fibrin-based strength only — platelet-blocked), INTEM (intrinsic pathway); fibrinogen guidance: FIBTEM A5 (amplitude at 5 minutes) or MCF (maximum clot firmness); threshold for fibrinogen concentrate: FIBTEM MCF < 7-9mm; dose calculation: fibrinogen grams = (target MCF - current MCF) × estimated blood volume correction factor; typical doses: two to four grams per treatment; re-test after administration confirming adequate fibrinogen restoration; advantages: fifteen to twenty-minute bedside results guiding targeted therapy.

How does TEG Functional Fibrinogen test compare to ROTEM FIBTEM? TEG Functional Fibrinogen (TEG-FF): TEG assay using reptilase and factor XIII activation with platelet inhibitor; measures fibrin-specific clot strength; parameter: FF Maximum Amplitude (FF MA) — normal ten to twenty-three mm; threshold for fibrinogen concentrate: FF MA < 10-14mm depending on clinical context; advantages versus ROTEM: cartridge-based system (TEG 6s) enabling point-of-care use; disadvantages: less published cardiac surgery literature versus ROTEM; institutional familiarity varies; both platforms validated for fibrinogen function assessment; clinical decision: use whichever platform institution has adopted with appropriate training and algorithm.

#FibrinogenConcentrate #ROTEM #FIBTEM #ViscoelasticTesting #GoalDirectedTherapy #TEGfibrinogen